Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Rocci, Alberto; Hofmeister, Craig C.; Geyer, Susan; Stiff, Andrew; Gambella, Manuela; Cascione, Luciano; Guan, Jingwen; Benson, Don M.; Efebera, Yvonne A.; Talabere, Tiffany; Dirisala, Vijaya R.; Smith, Emily; Omedè, Paola; Isaia, Gianluca; Luca, Luciana De; Rossi, Davide; Gentili, Silvia; Uccello, Giuseppina; Consiglio, Jessica; Ria, Roberto; Benevolo, Giulia; Bringhen, Sara; Callea, Vincenzo; Weiss, Brendan M.; Ferro, Alfredo; Magarotto, Valeria; Alder, Hansjüerg; Byrd, John C.; Boccadoro, Mario; Marcucci, Guido; Palumbo, Antônio

doi:10.1038/leu.2014.155

Cited by 54 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we know, MM evolves from a pre-malignant condition called Monoclonal Gammopathy of Undetermined Significance (MGUS) which progresses to MM at a rate of 1% in average [9,26]. It is noteworthy that breakthroughs are recently announced for the circulating miRNAs used as new prognosticators for MM [27]. In a former study, three serum microRNAs, miR-720, miR-1308 and miR-1246 were found to have potential as diagnostic biomarkers in MM, in which, miR-720 and miR-1246 generally decrease in MGUS and MM patients.…”

Section: Circulating Mirnas In Hematological Malignanciesmentioning

confidence: 99%

Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies

Cui¹,

Dong²

2014

J Leuk

View full text Add to dashboard Cite

Section: Circulating Mirnas In Hematological Malignanciesmentioning

confidence: 99%

Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies

Cui¹,

Dong²

2014

J Leuk

View full text Add to dashboard Cite

“…First, some well-known prognostic miRNA markers of MM [2][3][4][5]15 such as miR-19a were not identified. Since we focused on RRMMs with bortezomib failure and used the miRNA-array which contains just part (381 miRNAs) of the known human miRNAs, there is a possibility that some significant miRNA markers were missed.…”

Section: A B Cmentioning

confidence: 99%

“…Recently, circulating miRNA has been suggested as a minimally invasive prognostic marker for multiple myeloma (MM) including relapse, which may spare traditional invasive tumor cell examination by bone marrow biopsy. [2][3][4][5] However, circulating miRNA markers associated with the outcomes of Len-dex therapy have not been well studied. A better understanding of these can improve prediction of treatment outcome and selection of therapeutic options in the clinical setting.…”

mentioning

confidence: 99%

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

et al. 2017

View full text Add to dashboard Cite

“…A recent study showed that circulating miRNA could also be used for the prognosis of patients with MGUS and progression to MM. 28 Although many factors regulating tumor growth are tumor cell autonomous, they are insufficient to induce dissemination and progression, and a permissive microenvironment is required for frank malignancy to emerge. 29 A similar concept occurs in MM where the transition from MGUS to MM involves changes that occur due to the complex interaction of the malignant plasma cells with the microenvironment (Figure 1).…”

Section: Understanding the Molecular Mechanisms Of Progression In Smmmentioning

confidence: 99%

How I treat smoldering multiple myeloma

Ghobrial

Landgren

2014

Blood

View full text Add to dashboard Cite

Smoldering myeloma is a heterogeneous clinical entity where a subset of patients has an indolent course of disease that mimics monoclonal gammopathy of undermined significance, whereas others have a more aggressive course that has been described as “early myeloma.” It is defined as either serum M-protein ≥3 g/L or ≥10% monoclonal plasma cells in the bone marrow. There are currently no molecular factors to differentiate risks of progression for these patients. Current recommendations of therapy continue to be patient observation or patient enrollment in clinical trials. However, new definitions of active multiple myeloma recently agreed upon by the International Myeloma Working Group may alter the timing of therapy. On the basis of emerging data of therapy in these patients, it seems reasonable to believe that future recommendations for therapy of patients with smoldering myeloma will become an increasingly important topic. In this article, we review the current knowledge of this disease and risk factors associated with progression. We also examine biological insights and alterations that occur in the tumor clone and the surrounding bone marrow niche. Finally, we review clinical trials that have been performed in these patients and provide recommendations for follow-up of patients with this unique disease entity.

show abstract

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Abstract: N/

Cited by 54 publications

References 15 publications

Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies

Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

How I treat smoldering multiple myeloma

Contact Info

Product

Resources

About